Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Inclusion Criteria: In order to be to be eligible to participate in this study, an individual must meet all of the following criteria: * Histologically or cytologically confirmed non-squamous NSCLC that is metastatic (Stage IV), recurrent, or unresectable locally advanced (Stage IIIB/IIIC) disease, not amenable to treatment with curative intent. * No prior systemic therapy for advanced disease. Prior chemotherapy for local or locally advanced disease is allowed if completed \>6 months prior to trial enrollment. Prior immunotherapy is not allowed. * PD-L1 ≥ 1% using the 22c3 PD-L1 IHC assay or a local assay performed in a CLIA facility * Age ≥ 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * Life expectancy of at least 3 months. * Measurable disease as per RECIST v1.1 * Adequate bone marrow and organ function demonstrated by: * Absolute neutrophil count \>1,500/mm3 (1.5 × 10\^9/L). * Hemoglobin ≥ 8.0 g/dL not dependent on transfusion support. * Platelet count ≥ 75 × 10\^9/L (≥ 75,000 per mm3). * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5 × ULN without liver metastases; \< 5.0 x ULN if documented liver metastases * Serum total bilirubin ≤ ULN, or for patients with potential Gilbert's, direct bilirubin ≤ ULN * Calculated creatinine clearance ≥ 40 mL/min, using the Cockcroft-Gault formula. * Women of child-bearing potential (WOCBP) or men whose partner is a WOCBP agrees to use contraception while part…